In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.

FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion.

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...